24/7 Clinical Support: +1-800-737-6330 UDI Look-up · ISO 13485 QMS · HIPAA-ready connected care
Clinical sleep therapy article header
Resmed clinical article

Vetting a Medical Device Vendor: Three Scenarios, Three Different Checklists

· Lukas Neumann

One checklist doesn't fit every device purchase

I keep a folder of rejected vendor proposals. Forty-one of them at last count. When I went through it earlier this year—mostly because our medical director asked me to justify why we keep turning down the lowest bidder—I noticed the rejections weren't random. They clustered into three distinct problems. Not one problem. Three.

That's when I stopped trying to write a single due-diligence checklist for our procurement office and started writing three separate ones.

If you're a quality or compliance lead at a hospital, surgery center, or clinic, you've probably run into the same wall. The checklist that works for a zimmer-biomet implant evaluation doesn't work for a surgical catheter restock, and neither of them works when your imaging board starts asking about what is nuclear medicine and whether you should be offering it. Different question shapes require different answers.

So the article below is structured as three scenarios. Pick the one that sounds like your week.

Scenario A — You're buying a platform, not a product

This is the first-time adoption decision. If you're evaluating a robotic surgery system like the ROSA platform, or standing up a new zimmer-biomet knee line built around the Oxford partial or Persona total knee, or committing to a specific zimmer biomet acl surgical technique for your sports medicine program—you're in Scenario A. Platform decisions are the hardest to reverse, and they're the ones most procurement teams under-plan.

What to actually verify

  • Proctoring hours, not just "training available." I want to see a number and a named trainer.
  • Reference sites you can call. Insist on two or three, and ask their clinical staff directly—not their procurement office—how the learning curve felt.
  • Case-volume to competence. For any technique transfer—including the acl surgical technique piece if that's your angle—ask how many cases a surgeon typically needs before outcomes stabilize. Get a number, not a range.
  • Revision and back-out data in writing. Not a brochure. A letter headed by the vendor's clinical affairs team.
  • Contract exit terms at year five. If this doesn't work out, what does walking away cost us?

The counterintuitive part

Don't lead with price on a platform decision. I know that sounds backwards—especially if your CFO is breathing down your neck—but the total cost of a robotic system or a new implant line isn't the capital expense. It's three years of training gaps, missed cases, and surgeon frustration that slowly bleeds your OR schedule dry.

The cheapest capital quote on a platform is almost never the cheapest three-year decision. That's been my experience, anyway—though I should note we're a mid-size group doing around 180 procurement reviews a year. If you're a single-specialty clinic, the calculus might be shorter and cheaper to unwind.

Scenario B — You're restocking a consumable

This is where I lost real money. Not metaphorically. Fourteen thousand dollars, roughly—I want to say it was $14,200, but don't quote me on the exact figure.

We restocked 400 surgical catheters from a vendor we'd used twice before. Standard reorder. I skipped the lot-tolerance check because it was "basically the same as last time." It wasn't. The distal tip tolerance was off by enough that 60 of the 400 failed our pre-op verification. We ate the reorder at our own cost because the contract's tolerance clause was written for the spec sheet, not for lot-to-lot variance. A lesson learned the hard way.

Pacemaker restocks follow exactly the same rules—with a bigger penalty. No hospital wants to be the facility holding a device that later joins a manufacturer recall list.

What to actually verify

  • Lot consistency, not spec sheet consistency. These are not the same thing, and vendors will conflate them if you let them.
  • Expiry dating on every lot. Not just the lot being quoted today—the lots you'll be receiving in eight months.
  • Recall history. The FDA UDI database takes four minutes to check. Four minutes. That's it.
  • Vendor responsiveness on prior defects. If they were slow on a minor issue, they'll be slow on a major one.

Skipping the final check because we were rushing—because "it's basically the same as last time"—cost us more than any single verification would have. Five minutes of checking beats five days of correction.

Scenario C — You're evaluating a new modality

When our imaging board started asking whether we should offer nuclear medicine—meaning a modality where the clinical value depends as much on radiopharmaceutical supply chains as it does on the scanner—my existing vendor evaluation checklist was useless. Not because it was wrong, but because it was answering the wrong question.

Nuclear medicine is a diagnostic specialty that uses small amounts of radioactive tracers to image organ function, not just structure. The scanner matters. The isotope supply chain matters more. That second part is the one procurement teams underestimate.

What to actually verify

  • Isotope supply reliability. Ask for two named suppliers and their contingency plan when a reactor goes offline.
  • Staffing certification. Who on your current team can legally operate this on day one? If the answer is "we'll hire for it," budget 18 months, not 6.
  • Regulatory clearance for the specific indication. "Cleared for imaging" is not the same as "cleared for this indication."
  • Operating cost per scan, total. Not capital cost per scanner. Isotope, tech time, waste handling, shielding—all of it.

I can only speak to the procurement side of this one. If you're on the clinical side and evaluating whether nuclear medicine adds to your diagnostic mix, there are probably considerations I'm not aware of.

How to figure out which scenario you're in

Three questions. Answer them honestly, in order.

  1. Are you changing a workflow, or refilling a bin? Workflow change means Scenario A. Bin refill means B.
  2. Can the decision be reversed within 30 days at low sunk cost? If yes, you're in B. If no, you're in A or C.
  3. Do you have the staff to operate this on day one, without outside help? If the honest answer is "not yet," you're in C.

Most facilities don't have a single scenario problem—they have a mix in the same quarter. That's fine. The point isn't to solve one problem across your whole procurement office. It's to stop using the same checklist on three different questions and then blaming the checklist when it fails. (Note to self: put that line in the new onboarding deck.)

The one rule that survives all three

Prevention beats correction. I know that phrase is tired—burned into every slide deck in this industry—but it's the only rule I've found that holds across platform decisions, consumable restocks, and new modality evaluations equally.

The 12-point checklist I built after my third mistake has saved us an estimated $8,000 in potential rework. Not because it catches everything. Because it catches the five things that always seem to cost the most.

One caveat, and then I'll stop. My experience is based on roughly 180 procurement reviews a year at a mid-size hospital group—mainly orthopedic, cardiac, and interventional categories. If you're a small dental clinic buying zimmer-biomet products directly from a distributor, your checklist should be shorter. If you're a 900-bed system running formal value analysis committees on every line item, you need more layers, not fewer. The three-scenario frame is a starting point. Your mileage may vary depending on what's actually on your next purchase order.

Verify first. Correct rarely. That's the whole game.

Lukas Neumann

Lukas Neumann

Lukas Neumann is a respiratory and life-support equipment analyst covering critical-care ventilators, CPAP and BiPAP systems, oxygen concentrators, nebulizers, anesthesia workstations, and breathing-circuit accessories. He references ISO 80601-2-12 while assessing delivered tidal volume, pressure accuracy, trigger response, oxygen concentration, alarm behavior, battery endurance, humidification, gas consumption, and circuit resistance. His work helps respiratory therapists, intensive-care teams, clinical engineers, and buyers match ventilation performance, patient category, care setting, maintenance demands, and emergency readiness.